June 19, 2018 : DCMS #402

DISASTERS AVERTED — Near Miss Case Studies

Don’t Stop: Encouraging Patient Success

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Jeffrey Mechanick on Trans-Cultural Diabetes Care

HOMERUN SLIDES — Great Clinical Presentation Highlights

Future Use of Technology in Outpatient Care Part 3

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #130: Pathogenesis of Type 2 Diabetes Mellitus Part 1

MOST POPULAR ARTICLES OF THE MONTH

#1 Very Low Carbohydrate Diet Equals Better Diabetes Control
#2 Can’t Afford Insulin? There Are Options!
#3 Four New Drugs Waiting for Approval That Can Change the Diabetes Landscape (Part 1)

A few weeks ago we were  discussing DNA testing and the value this will have in medication choices. This week Steve shares an interview he had with Dr. Jeffrey Mechanick on a topic similar to our DNA discussion as they work their way through transcultural endocrinology and how this new way of looking at diabetes will likely define therapy choices for years to come.

Dave Joffe

Editor-in-chief

When prescribed lifestyle changes and or medication(s), patients who have diabetes, obesity, hypertension, or any chronic condition that is easy to monitor, even from home, may agree to these changes at first. They can almost immediately get improvements in their numbers. It can be encouraging. For some, seeing those numbers change for the better encourages them to keep on keeping on. However, others may think they are healed and stop treatment. Their numbers may go back to the same or even “worse” than before the treatment.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have another exclusive interview from the AACE 2018  in Boston, MA. Dr. Jeffrey Mechanick, MD, FACE, FACR, FACN, ECNU is Professor of Medicine and Medical Director of the Marie-Josée and Henry …

In this week’s Homerun Slides, asking the question of how to translate knowledge and implications of pathophysiology, progression, and diabetes complications to the prevention, early diagnosis and optimal treatment of diabetes and its complications.

Normal glucose homeostasis: Any discussion of the pathogenesis of type 2 diabetes mellitus (T2DM) must start with a review of mechanisms involved in the maintenance of normal glucose homeostasis in the basal o postabsorptive state (10–12-h overnight fast) and following ingestion of a typical mixed meal. In the postabsorptive state the great majority of total body glucose disposal takes place in insulin independent tissues.

Low carbs equals lower blood sugars and control, with less hypoglycemia, but how low do our patients need to go?

We all know the benefits of the newer insulins, i.e., faster action times, less peak from the long actings, etc. But the cost, more often than we know, can lead to patients decreasing insulin doses, doing without until the next payday, or doing without it altogether, as we’ve read about. (See David Kliff’s recent article.) …

Two of the four exciting treatment options currently being trialed could change the way the disease is treated long term.